INTRODUCTION
Helicobacter pylori infection is associated with many gastroduodenal disorders such as chronic gastritis, peptic ulceration, gastric mucosa-associated lymphoid tissue lymphoma, and gastric carcinoma. 1±5 However, the precise pathological process involved in the development of these disorders remains unclear. It has been reported that H. pylori increases proliferation of gastric epithelial cells and curing of the infection returns cell proliferation to normal levels. 6±8 The hyperplastic changes observed in H. pylori-induced gastritis are thought to be associated with pre-cancerous changes. 9, 10 The mechanisms involved in these changes are not yet clear.
Cyclooxygenase (COX) is the rate-limiting enzyme in the production of prostanoids [prostaglandins (PGs) and thromboxanes] from arachidonic acid. Several recent studies have con®rmed that there are two forms of cyclooxygenase: a constitutively produced COX-1 and inducible COX-2.
11±13 COX-1 is thought to participate in the production of tissue prostaglandin under normal physiological conditions, whereas COX-2 is induced by cytokines, growth factors and tumour promoters, and its expression has been characterized as an immediate± early response in in¯ammation. 14±16 Recently, elevated COX-2 expression has been demonstrated in human and rodent colorectal adenomas and carcinomas. 17±20 Importantly, inhibition of COX by non-steroidal anti-in¯ammatory drugs (NSAIDs) such as sulindac and piroxicam results in both regression of neoplastic SUMMARY Background and aims: The hyperplastic changes observed in Helicobacter pylori-associated gastritis have been considered to increase the risk of gastric cancer. The aim of this study was to determine whether cyclooxygenase-2 is involved in the hyperplastic changes in mice infected with H. pylori. Methods: Seven-week-old, male C57BL/6 mice (n 40) were inoculated with the Sydney strain of H. pylori. Control mice (n 40) were treated with vehicle only. Half of the infected and control mice were fed an experimental diet containing etodolac (10 mg/kg/day) from 1 week after inoculation until the end of the polyps and prevention of their development in individuals with familial adenomatous polyposis, as well as in murine models of this disease such as the Min mouse and APC knockout mouse. 17, 21, 22 In humans, increased COX-2 expression is observed in H. pyloriinduced gastritis and gastric adenocarcinomas.
23±25
Epidemiological studies have revealed that the use of aspirin and other NSAIDs decreases the risk of gastric cancer. 26, 27 However, limited information is available regarding the role of COX-2 in such H. pylori-associated disorders.
Recently, an H. pylori-infected C57BL/6 mouse model was established using the Sydney strain of H. pylori isolated from a human subject. 28 In this model, a large number of bacteria are visible on gastric mucosa, as observed in H. felis-infected animals and humans infected with H. pylori. 29 Chronic active gastritis are also observed after H. pylori inoculation. On the basis of the backgrounds, as discussed above, we examined whether COX-2 is involved in the development of hyperplastic gastritis in this H. pylori-infected C57BL/6 mouse model.
MATERIALS AND METHODS

Animals
Ninety, 7-week-old speci®c pathogen-free male C57BL/6 mice with an average body weight of 25 g were purchased from Seiwa Experimental Animal Ltd (Fukuoka, Japan) and housed in polycarbonate cages in isolators under a 12-h light/12-h dark cycle. The animals used in this study were cared for in accordance with our institutional guidelines.
Bacteria
The strain SS1 of H. pylori was kindly provided by Lee et al., who originally established the H. pylori-induced C57BL/6 mouse gastritis model. 28 This strain is positive for both cytotoxin-associated protein (CagA) and vacuolating cytotoxin (VacA). The bacteria were inoculated onto plated agar media supplemented with vancomycin (10 mg/L), polymyxin B (2500 I.U./L) and amphotericin B (2 mg/L) for isolation of H. pylori (Poamedia, Eikenkagaku Co., Ltd, Tokyo, Japan). The plates were incubated under microaerobic conditions at 37°C for 4±5 days. Colonies were then transferred into Brucella broth (BBL, Becton Dickinson and Co., Cockeyville, MD) liquid medium supplemented with 10% horse serum and incubated for a further 24 h with agitation under the same conditions as described above.
Bacterial inoculation
The culture of H. pylori (0.5 mL, 2.5´10 8 colonyforming units) was administered orally to C57BL/6 mice three times in a 5-day period using a metal stomach catheter. The control groups were inoculated with Brucella broth liquid medium without H. pylori.
Treatment of C57BL/6 mice with inhibitor of COX-2 and experimental protocol Etodolac was used as a selective COX-2 inhibitor in this study. The selectivity of etodolac for COX-2:COX-1 is 10:1. 30 The experimental diet was prepared monthly by mixing etodolac 10 mg/kg/day with the pellet diet and stored at 4°C until feeding. Eighty C57BL/6 mice were randomly distributed into uninfected (H. pylori-negative) or infected (H. pylori-positive) groups (40 for each group). Both control and experimental groups were divided into vehicle-treated sub-groups (H. pylori-negative/etodolac-negative, H. pylori-positive/etodolac-negative) and etodolactreated groups (H. pylori-negative/etodolac-positive, H. pylori-positive/etodolac-positive). The etodolactreated groups were administered etodolac diet from 1 week after inoculation. The regimen was continued until the end of the experiment. Ten mice in each group were weighed and sacri®ced under anaesthesia with ether before, or 12 and 24 weeks after inoculation. The stomach was excised and weighed. It was then cut along the greater curvature, and the surface of the mucosa was inoculated onto the H. pylori isolation agar plate as described above. The plates were incubated for 4±5 days at 37°C under the same conditions as described above. The bacterium cultured was identi®ed as H. pylori on the basis of results of urease, catalase and oxidase assays.
Half of the stomach was placed in 10% buffered formalin and embedded in paraf®n, and 4-lm sections were cut from the body to the antrum. The sections were stained with haemotoxylin-eosin for histological evaluation and with Giemsa to assess bacterial colonization. The other half was used for extraction of total RNA and proteins for competitive reverse transcription-polymerase chain reaction (RT-PCR) and western blotting analyses, as described below.
Histology and quanti®cation of mucosal thickness H&E-and Giemsa-stained sections were carefully screened for the presence of spiral H. pylori-like organisms. The in®ltration of polymorphonuclear cells and lymphocytes was also evaluated. The thickness of pits and glands of gastric mucosa was measured with a micrometer (OCM 1 10´10 SG; Olympus, Tokyo, Japan) on H&E-stained sections. Brie¯y, the gastric mucosa was scanned along the middle zone of the body, which was sectioned vertically to the surface of the gastric mucosa, where hyperplastic changes were predominantly observed. The pathologist choosing the section to scan was blinded to the identity of the treatment group. Values are expressed as the means of measurements along three or more foveolae. Total mucosal thickness was calculated by adding the thickness of the pit to that of the gland.
Competitive reverse transcription-polymerase chain reaction analysis for COX-2 mRNA Total RNA was extracted from the gastric mucosa of C57BL/6 mice immediately after the removal of the stomach. RNA extraction was performed using a commercial kit (RNA zoll Tel. Test, Inc., Friendwood, TX). RNA content was quanti®ed by measuring optical density (OD) at 260 nm (1.0 OD 260nm 40.0 lg/mL). Aliquots of 5 lg of RNA solution were subjected to reverse transcription. RNA was deposited by ethanol and dried under vacuum. The RNA pellet was dissolved in a reverse transcription mixture containing, in a ®nal volume of 100 lL, 20 lL of 5´First Strand Buffer, 10 lL of 0.1 M DTT, 1 lL of Oligo (dT) 12±18 (Gibco BRL, Life Technologies, Inc., Rockville, MD), 5 lL of mixed dNTP Stock (10 mM each of dATP, dGTP, dCTP, and dTTP at neutral pH) (Takara Shuzo Co., Ltd, Shiga, Japan), and 2.5 lL of RNasin Ribonuclease Inhibitor (Promega, Madison, WI). The mixture was heated at 70°C for 5 min, and rapidly chilled in ice. The RNA mixture was converted to (Figure 1 ). 19 The competitor was constructed ( Figure 1 ) using a commercial Competitive DNA Construction Kit (Takara Shuzo, Co., Ltd, Shiga, Japan) according to the manufacturer's instructions. Eight precise 10 0.5 -fold serial dilutions ranging from 1.0´10 ±0.5 pg/lL to 1.0´10 ±4 pg/lL of competitor were prepared in relatively large volumes so that the same dilution series could be used for measurement of many samples under identical conditions. We prepared a master mixture containing, in a ®nal volume of 50 lL, 5 lL of 10´PCR buffer [100 mM TrisHCl (pH 8.3), 500 mM KCl, 15 mM MgCl 2 , 0.1% gelatin], dNTPs (each at a ®nal concentration of 200 lM), oligonucleotide primers (COX-2 forward primer and COX-2 reverse primer, each at a ®nal concentration of 0.5 lM), 1.25 units of Taq polymerase (Ex Taq, Takara Shuzo, Shiga, Japan), and 1.0 lL of cDNA solution. An aliquot of 48 lL of this mixture was added to 2.0 lL of previously prepared competitor of known concentration in a dilution series. PCR was performed with an automatic thermal cycler (DNA Thermal Cycler PJ2000, Perkin-Elmer, Norwalk, Conn., USA). The ampli®cation consisted of an initial denaturation at 94°C for 5 min, followed by denaturation at 94°C for 30 s, annealing at 65°C for 30 s, and polymerization at 72°C for 1 min. The ®nal cycle included extension for 7 min at 72°C to ensure full extension of the product. COX-2 cDNA was ampli®ed through 35 consecutive cycles. PCR products (10 lL) were electrophoretically separated on 3.0% (wt/vol) agarose gels containing 0.5 lg/mL ethidium bromide in 1´TAE (Tris Acetone EDTA) buffer. The bands were visualized by excitation with UV light, and bands of 276 bp (COX-2) and 200 bp (competitor) were detected ( Figure 2A ). The gels were photographed and the intensity of ethidium bromide luminescence was measured with a CCD image sensor (Densitograph AE-6900-F, Atto, Tokyo, Japan), and the ratio of the 276 bp (COX-2) band to the 200 bp band (competitor) was plotted for each dose of competitor added to the reaction tube. The point of equivalence (that is, where there was a 1:1 ratio) was where COX-2 equalled the competitor and represented the concentration of COX-2 mRNA in the unknown sample ( Figure 3A) . The amount of b-actin mRNA was also measured by a similar method (Figures 2B and 3B ). The sequences of oligonucleotide primers for b-actin (Clontech, Inc., USA) and the competitive template are shown in Figure 1 . The amount of COX-2 mRNA in the gastric mucosa was standardized relative to b-actin and expressed as the COX-2:b-actin ratio.
Western blotting for COX-2
The gastric mucosa was homogenized at 4°C in lysis buffer [9.1 mM dibasic sodium phosphate, 1.7 mM monobasic sodium phosphate, 150 mM NaCl, 1% lgepel CA-630 (Sigma Chemicals), 0.5% sodium deoxycholate, 0.1% SDS], containing 30 lL/mL aprotinin (Sigma Chemicals), 1 mM sodium orthovanadate, and 100 lg/mL phenylmethylsulphonyl¯uoride. The homogenate was centrifuged twice at 14 000 r.p.m. for 20 min at 4°C. The supernatant was the protein lysate. The protein concentration was measured by Lowry's assay with BSA as the standard. The protein lysate was mixed with an equal volume of sample buffer and denatured at 94°C for 2 min. Equal amounts of protein (40 lg/lane) were separated by SDS-polyacrylamide gel electrophoresis (PAGE) and then transferred on to Hybond ECL nitrocellulose membranes (Amersham Inc., Buckinghamshire, UK) by electroblotting. The transfer of protein and equal loading in all lanes were veri®ed using reversible staining with Ponceau S. 31 The membranes were incubated for 1 h at room temperature in blocking solution [Tris-buffered saline (10 mM Tris-HCl, pH 8.0; 150 mM NaCl) containing 5% non-fat dried milk and 0.05% Tween 20], followed by overnight incubation with a polyclonal goat anti-mouse COX-2 antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA) at 1:250 dilution in blocking solution. Filters were washed three times for 5 min each with blocking solution, then probed with alkaline phosphataseconjugated donkey anti-goat immunoglobulin (Santa Cruz Biotechnology Inc., Santa Cruz, CA) as the secondary antibody at 1:1000 dilution in blocking solution for 30 min. After three additional washes with blocking solution followed by one wash for 5 min with AP buffer (100 mM Tris-HCl, pH 9.5; 100 mM NaCl; 5 mM MgCl 2 ), ®lters were treated with BM Purple AP substrate (Boehringer Mannheim GmbH, Germany). One sample from gastric mucosa of a C57BL/6 mouse infected by H. pylori for 24 weeks was used as a standard for measurement of other different samples. Bands were detected with a CCD image sensor (Densitograph AE-6900-F, Atto, Tokyo, Japan). The amount of COX-2 protein in gastric mucosa was standardized relative to the positive control infected with H. pylori for 24 weeks and expressed as the sample COX-2/positive control ratio. Representative results are shown in Figure 4 . The right lane (H. pylori inoculation for 24 weeks) was used as a standard for measurement of different samples.
Measurement of PGE 2
The gastric mucosa was homogenized at 4°C in lysis buffer. Next, the sample was vortexed. Homogenates were centrifuged at 14 000 r.p.m. for 20 min at 4°C. An aliquot of 10 lL from each sample was used to determine protein concentration with Lowry's assay. The supernatant from each sample was subjected to a PGE 2 assay. Determination of PGE 2 levels by enzyme immunoassay was accomplished using a Prostaglandin-E 2 -Monoclonal Enzyme Immunoassay Kit (Caymen Chemical, Ann Arbor, MI), according to the manufacturer's protocol. Plates were read at 410 nm with a plate reader (Delta SOFT 4.0B BioMetallics, Inc., Japan).
Statistical analysis
All numerical data are presented as means S.E.M. Whether body and stomach weights, COX-2 mRNA, COX-2 protein, and PGE 2 levels in gastric mucosa, and thickness of gastric pit differed among the four groups (H. pylori-negative/etodolac-negative, H. pylori-negative/etodolac-positive, H. pylori-positive/etodolac-negative, H. pylori-positive/etodolac-positive) was determined by one-way ANOVA followed by Fisher's multiple comparison test. Whether body and stomach weights, COX-2 mRNA, COX-2 protein, and PGE 2 levels in gastric mucosa, and thickness of gastric pit changed from before to 12 or 24 weeks after inoculation in each study group was determined by the Student's t-test. Pearson's correlation coef®cient was calculated to analyse the relationship between thickness of the gastric pits and the gastric mucosa. Statistical calculations were carried out with SAS software (SAS Institute, Cary, North Carolina). All P-values are two-sided and P < 0.05 was considered signi®cant.
RESULTS
H. pylori infection, body and stomach weight of C57BL/6 mice H. pylori was detected in all infected animals throughout the study. Bacterial colonization was detectable on Giemsa staining, and the bacteria cultured were identi®ed as H. pylori by urease, catalase and oxidase assays. The mean body weight of each of the four study groups increased in a time-dependent manner from before to 12 and 24 weeks after inoculation. No signi®cant intergroup differences were observed during the study period (data not shown). The mean stomach weight of the H. pylori-positive/ etodolac-negative group at 24 weeks after inoculation was signi®cantly increased compared with those before and 12 weeks after inoculation (P < 0.001 and P < 0.05), and was signi®cantly heavier than those of the H. pylori-negative/etodolac-negative (P < 0.001), and H. pylori-positive/etodolac-positive (P < 0.05) groups ( Figure 5 ). Differences in mean stomach weights observed at 12 weeks after inoculation were not statistically signi®cant.
Histopathological changes
At 12 weeks after inoculation, mild in®ltration of polymorphonuclear cells and lymphocytes was observed in both the antrum and body, mainly in the submucosa in the H. pylori-positive/etodolac-negative group. However, the in¯ammation was clearly more severe in the transitional zone between the antral and body mucosa ( Figure 6F ). At 24 weeks after inoculation, in®ltration of lymphocytes and plasma cells became prominent, and multifocal elongation of the gastric pits was observed in the gastric body with variable sparing of the antrum ( Figure 6G ). The thickness of the gastric pits was signi®cantly increased in the H. pylori-positive/etodolac-negative group at 24 weeks after inoculation in comparison with that in the H. pylori-negative/etodolacnegative group (268.8 37.2 vs. 64.0 7.5, P < 0.0001). The thickness of the gastric pits in the H. pylori-positive/etodolac-positive group was signi®- Figure 5 . Changes in means of stomach weights of C57BL/6 mice from before to 12 and 24 weeks after inoculation in the four study groups. At 24 weeks after inoculation, the means of stomach weights in the H. pylori-positive/etodolac-negative group was signi®cantly increased compared with those before and at 12 weeks after inoculation, and was signi®cantly heavier than those of the H. pylori-negative/etodolac-negative group (**P < 0.001) and H. pylori-positive/etodolac-positive group (*P < 0.05). No statistically signi®cant differences were observed among the four groups at 12 weeks after inoculation.
cantly decreased compared with that in the H. pyloripositive/etodolac-negative group (128.0 13.6 vs. 268.8 37.2, P < 0.001), but was greater than that in the H. pylori-negative/etodolac-negative group (128.0 13.6 vs. 64.0 7.5, P < 0.05) (Figures 6  and 7A ). There was an increase in thickness of both gastric pits and glands with multifocal erosions on the pit surface in the H. pylori-infected groups. The increase in total mucosal thickness was associated with an apparent increase in gastric pit thickness (r 0.918, P < 0.0001; Figure 8 ), but not with an increase in gastric gland thickness. Densities of H. pylori on Giemsa stained specimens did not differ between etodolacpositive and etodolac-negative groups. Figure 6 . Histopathological changes in H&E-stained sections at before, 12 and 24 weeks after inoculation in the four study groups. In the H. pylori-negative/etodolac-negative (A, B and C) and H. pylori-negative/etodolac-positive (A, D and E) groups, no histological changes were observed throughout the study period. In the H. pylori-positive/etodolac-negative, mild (F) and moderate (G) in®ltration of monoand poly-nuclear cells was observed and the thickness of the gastric mucosa gradually increased from before to 12 (F) and 24 (G) weeks after H. pylori inoculation. In the H. pylori-positive/etodolac-positive group at 24 weeks after inoculation (I), mucosal thickening was observed, but to a lesser extent than that of the H. pylori-positive/etodolac-negative group at 24 weeks after inoculation. At 12 weeks after inoculation, no mucosal thickening was observed in the H. pylori-positive/etodolac-positive group (H). Original magni®cation,´10.
COX-2 mRNA expression
Competitive reverse transcription-polymerase chain reaction analysis showed that COX-2 mRNA levels in the gastric mucosa in the H. pylori-positive/etodolacnegative group 24 weeks after inoculation were signi®cantly increased compared with those before and 12 weeks after inoculation (P < 0.01 and P < 0.05, respectively), and were signi®cantly higher than that in the H. pylori-negative/etodolac-negative group 24 weeks after inoculation (P < 0.001; Figure 7B ). Before inoculation and at 12 weeks after inoculation, COX-2 mRNA levels in the gastric mucosa in the H. pylori-positive/etodolac-negative group were not signi®cantly different from those in the H. pylorinegative/etodolac-negative group. No statistically signi®cant differences in COX-2 mRNA levels in the gastric mucosa were observed between the H. pyloripositive/etodolac-negative and H. pylori-positive/etodolac-positive groups or between H. pylori-negative/ Figure 7 . Changes in thickness of gastric pits (A), COX-2 mRNA (B), COX-2 protein (C), and PGE 2 (D) levels in the gastric mucosa from before to 12 and 24 weeks after inoculation in the four study groups. In the H. pylori-positive/etodolac-negative groups 24 weeks after inoculation, the above parameters were signi®cantly increased compared with those before inoculation and in the uninfected control groups. In the H. pylori-positive/etodolac-positive group 24 weeks after inoculation, the thickness of the gastric pits and PGE 2 levels in the gastric mucosa were signi®cantly decreased compared with those in the H. pylori-positive/etodolac-negative group (A and D). However, no statistically signi®cant changes were observed in COX-2 mRNA and protein levels in the gastric mucosa (B and C). **P < 0.001, *P < 0.05. etodolac-negative and H. pylori-negative/etodolacpositive groups. Etodolac dosing had no effect on COX-2 mRNA levels in H. pylori-infected or -uninfected groups.
COX-2 protein
As shown in Figure 7(C) , western blotting analysis demonstrated that the amount of COX-2 protein in the gastric mucosa in the H. pylori-positive/etodolac-negative group at 24 weeks after inoculation was signi®-cantly increased compared with that before inoculation (P < 0.05) and was signi®cantly higher than that of the H. pylori-negative/etodolac-negative group (P < 0.05), consistent with the levels of COX-2 mRNA. Before inoculation and at 12 weeks after inoculation, COX-2 protein levels in the gastric mucosa in the H. pyloripositive/etodolac-negative group were not signi®cantly different from those of the H. pylori-negative/etodolacnegative group. No signi®cant changes were observed in COX-2 protein levels following etodolac treatment in either H. pylori-infected or -uninfected groups at 24 weeks after inoculation, indicating that etodolac does not inhibit COX-2 expression.
PGE 2 levels
In the H. pylori-uninfected groups (H. pylori-negative/ etodolac-negative and H. pylori-negative/etodolacpositive groups), PGE 2 levels in the gastric mucosa were not changed signi®cantly from before to 12 and 24 weeks after inoculation. At 12 weeks after inoculation, the PGE 2 level in the infected group was not signi®cantly different from that in the control group. However, the PGE 2 level in the gastric mucosa in the H. pylori-positive/etodolac-negative group at 24 weeks after inoculation was signi®-cantly higher than those in the H. pylori-negative/ etodolac-negative and the H. pylori-negative/etodolacpositive groups at 24 weeks after inoculation and before inoculation (30.4 4.1 vs. 16.4 2.1, 12.7 1.9 , and 14.2 2.1; P < 0.05, P < 0.001, and P < 0.05, respectively). The PGE 2 level in the gastric mucosa in the H. pylori-positive/etodolac-positive group was signi®cantly lower than that in the H. pylori-positive/ etodolac-negative group (19.1 1.9 vs. 30.4 4.1, P < 0.05; Figure 7D ).
DISCUSSION
H. pylori-induced gastritis has recently been reported to be associated with increased epithelial proliferation.
6±8
NSAIDs were shown to reverse H. pylori-induced proliferation in gastric epithelial cells in human subjects. 32 However, the precise mechanisms by which H. pylori infection induces hyperplastic gastritis have not been elucidated. The present study, using C57BL/6 mice infected with the strain SS1 of H. pylori, revealed that COX-2 plays an important role in the development of hyperplastic changes in H. pylori-infected gastric mucosa.
In humans, a possible association of gastric hyperplastic changes (e.g. hyperplastic gastritis, hyperplastic polyps) with H. pylori infection has been reported, and in this study hyperplastic gastric polyps disappeared after cure of H. pylori infection in more than 40% of patients. 33 Stolte et al. examined 138 patients with hyperplastic gastritis and found that 90% were infected with H. pylori. 34 In their study, there seemed to be marked H. pylori colonization and a higher degree of gastritis in the corpus of the stomach compared with the antrum, as reported in H. felis-infected C57BL/6 mice. 29 In the present study, we determined changes in gastric mucosal thickness after H. pylori inoculation in C57BL/6 mice, and showed that H. pylori infection caused hyperplastic gastritis with marked colonization by this bacterium. COX-2 is involved in various in¯ammatory responses such as H. pylori gastritis, in¯ammatory bowel diseases Figure 8 . Correlation between the total mucosal thickness and the gastric pit thickness at 24 weeks after inoculation. A signi®-cant correlation was observed (r 0.918, P < 0.0001).
and gastric cancer in humans. 23, 25, 35 NSAIDs were shown to abrogate the proliferation effects induced by H. pylori infection in gastric epithelial cells in humans. 32 Epidemiological and experimental studies have revealed that NSAIDs, particularly aspirin, sulindac and piroxicam, are promising candidates as chemopreventive agents against the development of colorectal cancer and gastric cancer. 22, 26, 27, 36±38 The target enzyme of NSAIDs is assumed to be COX-2, an inducible isotype of COX. 12±14 The detailed roles of COX-2 in H. pyloriassociated hyperplastic gastritis have not, however, been clari®ed.
In most previous reports, COX-2 expression was thought to be induced under pathological conditions. Our results indicated that COX-2 was, however, constitutively expressed in the normal gastric mucosa of C57BL/6 mice, which coincided with the observations of Zimmermann et al. in the healthy human and rabbit gastric mucosa. 39 Using immunoblotting analysis, low but detectable levels of COX-2 protein were demonstrated in microsomes prepared from gastrointestinal tissues of normal rats. 40 Similarily, low levels of COX-2 mRNA and protein expression were observed in endothelial cells of the microvessels and basement membranes, and mucosal macrophages of normal human gastric mucosa. 41 COX-2 was also detected in myo®broblasts and endothelial cells of unstimulated human gastric mucosa and was expressed constitutively in human gastric endothelial cells in culture. 42 These ®ndings, taken together with our results, suggest that COX-2 is constitutively expressed in normal gastric tissue as well as COX-1. However, the role of constitutively expressed COX-2 is unclear. In the present study, the selective COX-2 inhibitor etodolac had no effect on gastric mucosa in relation to mucosal thickness and PGE 2 levels in gastric tissue in the H. pylori-uninfected groups. Therefore, the role of constitutively expressed COX-2 in normal gastric mucosa is assumed to be of limited signi®cance. On the other hand, in the present study, expression of COX-2 was markedly up-regulated in the mRNA level in the gastric mucosa of C57BL/6 mice infected with H. pylori compared with those of the control groups at 24 weeks after inoculation and was corroborated by the ®nding of an increase in COX-2 protein, along with the appearance of hyperplastic gastritis. Moreover, when the selective COX-2 inhibitor etodolac was continuously administered soon after inoculation, PGE 2 levels in gastric tissue were signi®cantly decreased and the hyperplastic changes were signi®cantly suppressed. This suggests that COX-2 induced by H. pylori infection might play an important role in the development of hyperplastic gastritis through an increase in PGE 2 level, and that this process might be inhibited by etodolac. However, as shown in Figures 6 and 7 , the selective COX-2 inhibitor did not completely inhibit hyperplastic changes. This suggests that other factors such as gastrin and several growth factors [e.g. transforming growth factor-alpha (TGF-a), epidermal growth factor (EGF), hepatocyte growth factor (HGF), and ®broblast growth factor (FGF)], may be also involved in hyperplastic changes in H. pylori infection. 43, 44 Previously, a slight increase (less than twofold) in antral PGE 2 levels was reported in patients infected with H. pylori, but this was not statistically signi®cant. 45 Patients taking no NSAIDs in this previous study showed a threefold increase in PGE 2 levels with H. pylori infection in comparison with those taking NSAIDs, and this effect was statistically signi®cant. Signi®cant increases in expression of mRNA and protein of COX-2 were also observed in H. pylori-positive gastritis. 23 In a previous immunohistochemical study, up-regulated expression of COX-2 was shown to be reduced after H. pylori eradication. 24 Therefore, expression of COX-2 in epithelial cells was assumed to be strongly correlated with the intensity of chronic in¯ammatory cell in®ltra-tion. Several studies have indicated that COX-2 expression is induced in several cell lines by growth factors and cytokines such as transforming growth factor-a, transforming growth factor-b and interleukin-1. 15, 46, 47 In the present study, increased expression of COX-2 was observed at 24 weeks after H. pylori inoculation, when apparent chronic active gastritis was observed, but not at 12 weeks after H. pylori inoculation, when only mild in®ltration of polymorphonuclear cells and lymphocytes were seen. Thus, increased expression of COX-2 was correlated with chronic in¯ammatory cell in®ltration in the gastric mucosa of C57BL/6 mice infected with H. pylori.
Tsujii et al. suggested a possible link between COX-2 and epithelial cell growth. 48 NSAIDs, agents that block the activity of COX-2, were shown to be associated with a decreased incidence of colon cancer, which is mediated by a decrease in COX-2 expression in colonic tumours, in a human study. 49 The preventive mechanisms have been postulated to involve inhibition of COX-2, and thus, production of eicosanoids such as prostaglandins, which in¯uence tumour growth either by directly participating in the signal cascade for cell proliferation or by disturbing immunological surveillance. 36, 37 In a murine model of familial adenomatous polyposis, the NSAIDs such as sulindac decreased COX-2 and PGE 2 levels to baseline in the small bowel and inhibited tumour formation. 38 Takahashi et al. reported that H. pylori increased the PGE 2 and HGF releases from human gastric ®broblasts and that these increased releases were inhibited by NSAIDs including a COX-2 speci®c inhibitor. 50 Several studies showed that H. pylori infection can cause increased gastric cell proliferation, which is assumed to play an important role in gastric carcinogenesis.
6±8 NSAIDs were shown to reverse H. pylori-induced proliferation in gastric epithelial cells. 32 In the present study, continuous administration of a selective COX-2 inhibitor, etodolac, signi®cantly inhibited the production of PGE 2 . This was suggested to result in a signi®cant reduction of hyperplastic changes in gastric mucosa of C57BL/6 mice at 24 weeks after H. pylori inoculation, compared with the controls. These observations indicate that increased expression of COX-2 plays a crucial role in the hyperplastic changes in the gastric mucosa induced by H. pylori infection.
CONCLUSION
In summary, our results suggest that increased expression of COX-2 has a crucial role in the hyperplastic changes associated with gastritis induced by H. pylori infection, which is mediated by PGE 2 . The COX-2-selective inhibitor etodolac may be useful for the prevention and treatment of H. pylori-associated gastric hyperplasia, which may be related to the chemopreventive effect of NSAIDs against gastric carcinogenesis.
